AG˹ٷ

STOCK TITAN

[8-K] Inspire Medical Systems, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

StoneX Group Inc. (SNEX) � Form 4 insider activity

Director John M. Fowler reported the award of 139 restricted common shares on 31 Jul 2025 (transaction code “A�) under the company’s Restricted Stock Program. The grant carries no cash price and will vest in three equal annual tranches. After the transaction Fowler now directly owns 116,874 SNEX shares and indirectly holds 3,000 shares through his spouse.

No sales, options, or other derivative transactions were disclosed. While the filing reflects continued insider alignment, the incremental shares represent less than 0.5 % of his current stake and are unlikely to be material to StoneX’s equity structure.

StoneX Group Inc. (SNEX) � Attività degli insider secondo il Modulo 4

Il direttore John M. Fowler ha segnalato la concessione di 139 azioni ordinarie vincolate il 31 luglio 2025 (codice transazione “A�) nell’ambito del Programma di Azioni Vincolate della società. La concessione non prevede alcun prezzo in denaro e si maturerà in tre tranche annuali uguali. Dopo questa operazione, Fowler possiede direttamente 116.874 azioni SNEX e detiene indirettamente 3.000 azioni tramite sua moglie.

Non sono state dichiarate vendite, opzioni o altre transazioni derivate. Sebbene la comunicazione evidenzi un allineamento continuo degli insider, le azioni aggiuntive rappresentano meno dello 0,5% della sua partecipazione attuale e probabilmente non avranno un impatto significativo sulla struttura azionaria di StoneX.

StoneX Group Inc. (SNEX) � Actividad de insiders según el Formulario 4

El director John M. Fowler reportó la adjudicación de 139 acciones ordinarias restringidas el 31 de julio de 2025 (código de transacción “A�) bajo el Programa de Acciones Restringidas de la compañía. La concesión no tiene precio en efectivo y se consolidará en tres partes iguales anuales. Tras la transacción, Fowler posee directamente 116,874 acciones SNEX y mantiene indirectamente 3,000 acciones a través de su cónyuge.

No se divulgaron ventas, opciones u otras transacciones derivadas. Aunque la presentación refleja una alineación continua de los insiders, las acciones adicionales representan menos del 0.5 % de su participación actual y es poco probable que sean significativas para la estructura accionaria de StoneX.

StoneX Group Inc. (SNEX) � 내부� 거래 보고�(Form 4) 활동

이사 John M. Fowler� 2025� 7� 31� 회사� 제한 주식 프로그램� 따라 139주의 제한 보통� 수여(거래 코드 “A�)� 보고했습니다. � 보조금은 현금 가격이 없으� 3년간 매년 동일� 비율� 취득됩니�. 이번 거래 � Fowler� 직접적으� 116,874주의 SNEX 주식� 보유하고 있으�, 배우자를 통해 간접적으� 3,000�� 보유하고 있습니다.

판매, 옵션 또는 기타 파생 거래� 공개되지 않았습니�. 이번 보고� 내부자들� 지속적� 일치� 입장� 보여주지�, 추가� 주식은 현재 지분의 0.5% 미만으로 StoneX� 주식 구조� � 영향� 미치지 않을 것으� 보입니다.

StoneX Group Inc. (SNEX) � Activité des initiés selon le Formulaire 4

Le directeur John M. Fowler a déclaré l�attribution de 139 actions ordinaires restreintes le 31 juillet 2025 (code de transaction « A ») dans le cadre du programme d’actions restreintes de la société. Cette attribution ne nécessite aucun paiement en espèces et sera acquise en trois tranches annuelles égales. Après cette opération, Fowler possède désormais directement 116 874 actions SNEX et détenait indirectement 3 000 actions par l’intermédiaire de son conjoint.

Aucune vente, option ou autre transaction dérivée n’a été divulguée. Bien que le dépôt reflète un alignement continu des initiés, les actions supplémentaires représentent moins de 0,5 % de sa participation actuelle et sont peu susceptibles d’avoir un impact significatif sur la structure du capital de StoneX.

StoneX Group Inc. (SNEX) � Insider-Aktivitäten gemäß Formular 4

Direktor John M. Fowler meldete die Zuteilung von 139 eingeschränkten Stammaktien am 31. Juli 2025 (Transaktionscode „A�) im Rahmen des Restricted Stock Programms des Unternehmens. Die Zuteilung erfolgt ohne Barzahlung und wird in drei gleichen jährlichen Tranchen freigegeben. Nach der Transaktion besitzt Fowler direkt 116.874 SNEX-Aktien und hält indirekt 3.000 Aktien über seine Ehefrau.

Es wurden keine Verkäufe, Optionen oder andere derivative Transaktionen offengelegt. Obwohl die Meldung eine fortgesetzte Übereinstimmung der Insider zeigt, machen die zusätzlichen Aktien weniger als 0,5 % seines aktuellen Anteils aus und dürften für die Aktienstruktur von StoneX unerheblich sein.

Positive
  • Director acquired 139 restricted shares, signalling ongoing insider alignment.
  • Total direct ownership increases to 116,874 shares, reinforcing long-term commitment.
Negative
  • Grant size is immaterial relative to both Fowler’s stake and StoneX’s float.
  • Shares were awarded, not open-market purchases, limiting the strength of the buying signal.

Insights

TL;DR: Small restricted-stock grant; positive alignment signal but negligible financial impact.

The Form 4 shows a routine award of 139 restricted shares to Director Fowler, boosting his direct stake to 116,874 shares. No open-market buying occurred, so cash outlay and signalling value are limited. Given StoneX’s float and Fowler’s existing holdings, the grant is immaterial to valuation or governance metrics. Investors should view the filing as neutral with a mild positive bias due to continued insider ownership.

StoneX Group Inc. (SNEX) � Attività degli insider secondo il Modulo 4

Il direttore John M. Fowler ha segnalato la concessione di 139 azioni ordinarie vincolate il 31 luglio 2025 (codice transazione “A�) nell’ambito del Programma di Azioni Vincolate della società. La concessione non prevede alcun prezzo in denaro e si maturerà in tre tranche annuali uguali. Dopo questa operazione, Fowler possiede direttamente 116.874 azioni SNEX e detiene indirettamente 3.000 azioni tramite sua moglie.

Non sono state dichiarate vendite, opzioni o altre transazioni derivate. Sebbene la comunicazione evidenzi un allineamento continuo degli insider, le azioni aggiuntive rappresentano meno dello 0,5% della sua partecipazione attuale e probabilmente non avranno un impatto significativo sulla struttura azionaria di StoneX.

StoneX Group Inc. (SNEX) � Actividad de insiders según el Formulario 4

El director John M. Fowler reportó la adjudicación de 139 acciones ordinarias restringidas el 31 de julio de 2025 (código de transacción “A�) bajo el Programa de Acciones Restringidas de la compañía. La concesión no tiene precio en efectivo y se consolidará en tres partes iguales anuales. Tras la transacción, Fowler posee directamente 116,874 acciones SNEX y mantiene indirectamente 3,000 acciones a través de su cónyuge.

No se divulgaron ventas, opciones u otras transacciones derivadas. Aunque la presentación refleja una alineación continua de los insiders, las acciones adicionales representan menos del 0.5 % de su participación actual y es poco probable que sean significativas para la estructura accionaria de StoneX.

StoneX Group Inc. (SNEX) � 내부� 거래 보고�(Form 4) 활동

이사 John M. Fowler� 2025� 7� 31� 회사� 제한 주식 프로그램� 따라 139주의 제한 보통� 수여(거래 코드 “A�)� 보고했습니다. � 보조금은 현금 가격이 없으� 3년간 매년 동일� 비율� 취득됩니�. 이번 거래 � Fowler� 직접적으� 116,874주의 SNEX 주식� 보유하고 있으�, 배우자를 통해 간접적으� 3,000�� 보유하고 있습니다.

판매, 옵션 또는 기타 파생 거래� 공개되지 않았습니�. 이번 보고� 내부자들� 지속적� 일치� 입장� 보여주지�, 추가� 주식은 현재 지분의 0.5% 미만으로 StoneX� 주식 구조� � 영향� 미치지 않을 것으� 보입니다.

StoneX Group Inc. (SNEX) � Activité des initiés selon le Formulaire 4

Le directeur John M. Fowler a déclaré l�attribution de 139 actions ordinaires restreintes le 31 juillet 2025 (code de transaction « A ») dans le cadre du programme d’actions restreintes de la société. Cette attribution ne nécessite aucun paiement en espèces et sera acquise en trois tranches annuelles égales. Après cette opération, Fowler possède désormais directement 116 874 actions SNEX et détenait indirectement 3 000 actions par l’intermédiaire de son conjoint.

Aucune vente, option ou autre transaction dérivée n’a été divulguée. Bien que le dépôt reflète un alignement continu des initiés, les actions supplémentaires représentent moins de 0,5 % de sa participation actuelle et sont peu susceptibles d’avoir un impact significatif sur la structure du capital de StoneX.

StoneX Group Inc. (SNEX) � Insider-Aktivitäten gemäß Formular 4

Direktor John M. Fowler meldete die Zuteilung von 139 eingeschränkten Stammaktien am 31. Juli 2025 (Transaktionscode „A�) im Rahmen des Restricted Stock Programms des Unternehmens. Die Zuteilung erfolgt ohne Barzahlung und wird in drei gleichen jährlichen Tranchen freigegeben. Nach der Transaktion besitzt Fowler direkt 116.874 SNEX-Aktien und hält indirekt 3.000 Aktien über seine Ehefrau.

Es wurden keine Verkäufe, Optionen oder andere derivative Transaktionen offengelegt. Obwohl die Meldung eine fortgesetzte Übereinstimmung der Insider zeigt, machen die zusätzlichen Aktien weniger als 0,5 % seines aktuellen Anteils aus und dürften für die Aktienstruktur von StoneX unerheblich sein.

0001609550False00016095502025-08-042025-08-04


SECURITIES AND EXCHANGE
Washington, D.C. 20549
_________________________
FORM 8-K
_________________________
CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 4, 2025
_________________________
INSPIRE MEDICAL SYSTEMS, INC.
(Exact name of registrant as specified in its charter)
_________________________
Delaware001-3846826-1377674
(State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
5500 Wayzata Blvd., Suite 1600
Golden Valley, Minnesota 55416
(Address of principal executive offices) (Zip Code)

(844) 672-4357
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par value per shareINSPNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company     

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 2.02.    Results of Operations and Financial Condition.

On August 4, 2025, Inspire Medical Systems, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 31, 2025, Randall A. Ban, Executive Vice President, Patient Access and Therapy Development, notified the Company of his intent to retire on January 30, 2026.

Item 7.01.     Regulation FD Disclosure.
In August and September of 2025, the Company will be participating in various meetings with investors and analysts, and a copy of the Company’s presentation materials being used at these meetings is furnished as Exhibit 99.2 hereto and is incorporated herein by reference. These presentation materials are also available on the Investor Relations page of the Company’s website at https://investors.inspiresleep.com.

The information in each of Item 2.02 and Item 7.01 of this Current Report on Form 8-K and in the press release attached as Exhibit 99.1 and the presentation attached as Exhibit 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01.    Financial Statements and Exhibits.
(d) Exhibits

Exhibit No.Description
99.1
Press release of Inspire Medical Systems, Inc., dated August 4, 2025.
99.2
Inspire Medical Systems, Inc. Presentation, August 4, 2025.
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INSPIRE MEDICAL SYSTEMS, INC.
Date:August 4, 2025By:/s/ Richard J. Buchholz
Richard J. Buchholz
Chief Financial Officer

3

FAQ

How many SNEX shares did John M. Fowler acquire?

He received 139 restricted shares on 31 Jul 2025.

What is Fowler’s total beneficial ownership after the grant?

He now directly holds 116,874 shares and indirectly holds 3,000 shares through his spouse.

Were any SNEX shares sold in this Form 4 filing?

No; the filing discloses only an acquisition and no dispositions.

When do the newly granted restricted shares vest?

They vest in three equal installments on each anniversary of the grant date.

Does the transaction involve any derivative securities?

No derivative securities were reported in this Form 4.
Inspire Medical

NYSE:INSP

INSP Rankings

INSP Latest News

INSP Latest SEC Filings

INSP Stock Data

3.72B
27.83M
1.11%
118.98%
11.16%
Medical Devices
Surgical & Medical Instruments & Apparatus
United States
GOLDEN VALLEY